<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="575">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/10/2005</approvaldate>
  <actrnumber>ACTRN12605000628640</actrnumber>
  <trial_identification>
    <studytitle>Acquisition and transmission of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis</studytitle>
    <scientifictitle>Acquisition and transmission of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This project is divided into four parts. Part one is designed to examine whether early acquisition of P.aeruginosa in young children with CF is associated with environmental sources of P.aeruginosa in the home. Part two is a methodology study designed to screen large numbers of microbiological samples for the predominant Brisbane clonal strain of P.aeruginosa. Part three allows an opportunity to explore the possible relationship between molecular factors that may be involved in acquisition and transmission of clonal strains of P.aeruginosa.  Part four examines culturable cough generated aerosols in patients with CF and an examination of clinical factors that may be involved in aerosol transmission of P.aeruginosa. It is anticipated that environmental sampling may take up to 2 years to complete and that clinical air sampling will take up to 12 months to complete.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To identify if aerosol contamination in the home environment provides the most likely source of P.aeruginosa for initial infection with P. aeruginosa</outcome>
      <timepoint>At time of testing</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine if transmission of P. aeruginosa is related to exposure time and infective load of aerosolised P. aeruginosa and specific virulence factors associated with the organism.</outcome>
      <timepoint>At time of testing</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To provide practical solutions that will contain the risks of cross-infection and  enable appropriate and optimal management of all patients with CF.</outcome>
      <timepoint>At time of analysis</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Children and adults diagnosed with cystic fibrosis at Royal Children's Hospital, Brisbane and The Prince Charles Hospital, Brisbane Informed consent from patients or parents/guardians.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Informed consent cannot be obtained.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/05/2005</anticipatedstartdate>
    <actualstartdate>6/10/2005</actualstartdate>
    <anticipatedenddate>31/12/2012</anticipatedenddate>
    <actualenddate>31/12/2012</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Claire Wainwright</primarysponsorname>
    <primarysponsoraddress>Herston Rd Herston</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>RCH Foundation, Brisbane</fundingname>
      <fundingaddress>Herston Rd Herston</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Scott Bell</sponsorname>
      <sponsoraddress>Rode Rd Chermside</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study has been designed to examine where first infections with Pseudomonas aeruginosa come from and also to examine the factors that may be important in how the organism might be passed from one person to another with CF.   </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/12/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Brisbane</address>
      <phone>+617 30681111</phone>
      <fax>+617 30697159</fax>
      <email>Claire.Wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms Joyce Cheney</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Brisbane</address>
      <phone>+617 30697195</phone>
      <fax>+617 30697159</fax>
      <email>Joyce.Cheney@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Joyce Cheney</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Brisbane</address>
      <phone>+617 30697195</phone>
      <fax>+617 30697159</fax>
      <email>joyce.cheney@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Claire Wainwright</name>
      <address>5a Respiratory &amp; Sleep Medicine
Lady Cilento Children's Hospital
Brisbane</address>
      <phone>+617 30681111</phone>
      <fax />
      <email>Claire.Wainwright@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>